Search All News
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.
New clinical trial studies the application of focused ultrasound technique to deliver chemotherapy in patients with DIPG, an aggressive type of brain cancer.
Source:CUIMC NewsroomJanuary 11, 2021
A study, led by HICCC members, has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.